Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2011-08-09
2011-08-09
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C800S003000, C435S007100
Reexamination Certificate
active
07993627
ABSTRACT:
This invention provides methods of screening compounds for their ability to alter the production of Aβ(x≧41) alone or in combination with Aβ(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of Aβ(x≦40) and Aβ(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
REFERENCES:
patent: 4271140 (1981-06-01), Bunting
patent: 4486530 (1984-12-01), David et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5134062 (1992-07-01), Blass
patent: 5200339 (1993-04-01), Abraham
patent: 5221607 (1993-06-01), Cordell et al.
patent: 5234814 (1993-08-01), Card et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5455169 (1995-10-01), Mullan
patent: 5538845 (1996-07-01), Knops et al.
patent: 5547841 (1996-08-01), Marotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5750349 (1998-05-01), Suzuki et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5850003 (1998-12-01), McConlogue et al.
patent: 5955317 (1999-09-01), Suzuki et al.
patent: 6018024 (2000-01-01), Seubert et al.
patent: 6610493 (2003-08-01), Citron et al.
patent: 123 527 (1984-10-01), None
patent: 171 496 (1986-02-01), None
patent: 173 494 (1986-03-01), None
patent: 184 187 (1986-06-01), None
patent: 391 714 (1990-10-01), None
patent: 444 856 (1997-09-01), None
patent: 62-100291 (1987-05-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 90/12870 (1990-11-01), None
patent: WO 90/12871 (1990-11-01), None
patent: WO 91/04339 (1991-04-01), None
patent: WO 91/16628 (1991-10-01), None
patent: WO 91/19810 (1991-12-01), None
patent: WO 92/00521 (1992-01-01), None
patent: WO 92/09699 (1992-06-01), None
patent: WO 92/13069 (1992-08-01), None
patent: WO 93/01817 (1993-02-01), None
patent: WO 93/08264 (1993-04-01), None
patent: WO 93/14200 (1993-07-01), None
patent: WO 93/16101 (1993-08-01), None
patent: WO 93/21526 (1993-10-01), None
patent: WO 94/00569 (1994-01-01), None
patent: WO 94/01772 (1994-01-01), None
patent: WO 94/10569 (1994-05-01), None
patent: WO 94/23049 (1994-10-01), None
patent: WO 96/15452 (1996-05-01), None
patent: WO 97/10601 (1997-12-01), None
patent: WO 97/48983 (1997-12-01), None
“Alzheimer's Assault,”ScienceScope, p. 1059 (Feb. 28, 1992).
Gene Targeting A Practical Approach, edited by Joyner, A.L., Oxford Univ. Press (1993) cover page, colophon, and table of contents.
Abraham et al., “A Calcium-activated Protease from Alzheimer's DiseaseBrain Cleaves at the N-terminus of the Amyloid β-protein”Biochem. Biophys. Res. Comm., 174(2):790-796 (1991).
Ali et al., “More Transgenic Mouse Studies of Alzheimer Amyloid Precursor (AAP) Proteins and Derivatives,”Society for Neuroscience Abstracts, 18(2):Abstract 616.8, 22nd Annual Meeting, Anaheim, CA Oct. 25-30, 1992.
Allison et al., “Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic β cells,”Nature, 333:529-533 (1988).
Allsop et al., “Immunohistochemical Evidence for the Derivative of a Peptide Ligand from the Amyloid .beta.-Protein Precursor of Alzheimer Disease,”PNAS, 85:2790-2794 (1988).
Anderson et al., “Exact Cleavage Site of Alzheimer Amyloid Precursor in Neuronal PC-12 Cells,”Neuroscience Letters, 128:126-128 (1991).
Antal et al., “Animal Models of Alzheimer's, Parkinson's and Huntington's Disease. A Minireview,”Neurobiology, 1(2):101-122 (1993).
Asami-Odaka et al., “Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells,”Biochemistry, 34(32):10272-10278 (1995).
Barrow et al., “Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition,”Science, 253:179-182 (1991).
Boller et al.,Biological Markers of Alzheimer's Disease, Springer-Verlag (Berlin), pp. 24-29 (1989).
Bullock et al.,Techniques in Diagnostic Pathology, vol. 2, pp. 100-112, Academic Press (London), (1991).
Burdick et al., “Assembly and aggregation of synthetic Alzheimer's A4/beta amyloid peptide analogs,”J. Biol. Chem., 267(1):546-554 (1992).
Buxbaum et al. “Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide,”PNAS, 90:9195-9198 (1993).
Cai et al., “Release of Excess Amyloid β Protein from a Mutant Amyloid Protein Precursor,”Science, 259:514-516 (1993).
Carroll et al., “An Age-Related Correlation Between Levels of .beta.-Amyloid Precursor Protein and .beta.-Amyloid in Human Cerebrospinal Fluid,”Biochem. Biophys. Res. Comm., 210(2):345-349 (1995).
Castano et al., “In Vitro Formation of Amyloid Fibrils from Two Synthetic Peptides of Different Lengths Homologous to Alzheimer's Disease .beta. Protein,”Biochem. Biophys. Res. Comm., 141(2):702-789 (1986).
Ceballos-Picot et al., “Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome,”Brain Research, 552:198-214 (1991).
Chartier-Harlan et al., “Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene,”Nature, 353:844-846 (1991).
Chiu et al.,Archive of Neurology, 50(1):57-63 (1993).
Citron et al., “Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production,”Nature, 360:672-674 (1992).
Cotton, R.G.H., “A G to C Transversion in Codon 258 of the α-Subunit of β-Hexosaminidase A in an Infant Tay-Sachs Disease Patient,”Human Mutation, 2:496-497 (1993).
Crawford et al., “Alzheimer's Disease Untangled,”BioEssays, 14(11):727-734 (1992).
De Strooper et al., “Study of the Synthesis and Secretion of Normal and Artificial Mutants of Murine Amyloid Precursor Protein (APP): Cleavage of APP Occurs in a Late Compartment of the Default Secretion Pathway,”J. Cell Biology, 121(2):295-304 (1993).
Dovey et al., “Cells with a familial Alzheimer's disease mutation produce authentic β-peptide,”NeuroReport, 4:1039-1042 (1993).
Dyrks et al., “Generation of .beta. A4 from the amyloid protein precursor and fragments thereof,”FEBS Letters, 335(1):89-103 (1993).
Epstein et al., “Transgenic mice with increased Cu/Zn-superoxide dismutase activity: Animal model of dosage effects in Down syndrome,”PNAS, 84:8044-8048 (1987).
Erickson, D., “Model Mice, Transgenic animals aid Alzheimer's research,” p. 34,Scientific American, (1991).
Esch et al., “Cleavage of amyloid β peptide during constitutive processing of its precursor,”Science, 248:1122-1124 (1990).
Estus et al., “Potentially Amyloidogenic, Carboxyl-Terminal Derivatives of the Amyloid Protein Precursor,”Science, 255:726-728 (1992).
Felsenstein et al., “Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing,” pp. 401-409 fromAlzheimer's and Parkinson's Diseases, edited by Hanin, I. et al., Plenum Press, New York, (1995).
Fidani et al., “Screening for mutations in the open reading frame and promoter of the β-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val Ile,”Human Molecular Genetics, 1(3):165-168 (1992).
Fisher et al., “Expression of the amyloid precursor protein gene in mouse oocytes and embryos,”PNAS, 88:1779-1782 (1991).
Forss-Petter et al., ȁ
Citron Martin
Schenk Dale B.
Selkoe Dennis J.
Seubert Peter A.
Alston and Bird LLP
Brigham and Women's Hospital
Duffy Patricia A
Elan Pharmaceuticals Inc.
LandOfFree
Methods for determining whether a compound alters the amount... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining whether a compound alters the amount..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining whether a compound alters the amount... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679202